Move beyond reporting.
Most biopharma teams are making real decisions on month-old, fragmented data and reports that stop at “here’s what happened.” PharmaForward builds intelligence products that go further: Digital Intelligence tells you what to do next. Benchmark Intelligence tells you where you stand against peers.
Referral signal concentration is shifting toward two priority territories. Reallocate paid coverage ahead of the pattern and close the locator citation gap before the next edition.
Illustrative edition. Sample data shown.
Digital Intelligence.
The report that tells you what to do next.
A recurring, interpreted intelligence report for pharma and rare disease brands. It pulls primary data from across the digital ecosystem, interprets it through PharmaForward’s analytical framework, and reads like a strategist wrote it. Every edition covers what changed, what it means commercially, and the specific moves to make next.
It ends with what to do
Standard reporting tells you what happened. Every edition tells you why it happened and the specific moves to make next, mapped to commercial impact rather than vanity metrics.
Primary data, integrated
Paid search, organic, AEO/GEO findability, web behavior, referral and B2B visitor signals, combined into one read. An interpreted view of the full program, never a single-platform export.
Built for rare disease reality
The analytical framework is purpose-built for specialty and rare disease commercial reality, where a single HCP referral can carry millions in treatment value and averages hide everything that matters.
Written like analysis, not a dashboard
Delivered bi-weekly as a publication-quality interactive report, with an email digest of the highlights and the full edition a click away. You are never left to decode a dashboard yourself.
Digital Benchmark Intelligence.
How do you compare to peers?
Most digital reports answer one question: what happened? Benchmark Intelligence answers the more important one. Drawing on aggregated, anonymized performance data across pharmaceutical, biotech, and healthcare digital programs, it shows whether your engagement, search visibility, conversion rates, and digital experience are leading, average, or underperforming, and where the gap is worth closing.
Illustrative scorecard. Marker shows peer median.
- Website engagement and content performance
- Search and AI visibility (SEO, AEO, GEO)
- Conversion and lead-generation effectiveness
- User experience and site performance
- Channel and campaign contribution
- Digital maturity and analytics readiness
- Custom benchmark scorecard
- Peer and industry comparisons
- Opportunity and risk assessment
- Executive summary and recommendations
- Quarterly trend analysis and progress tracking
Commercial, brand, medical affairs, patient engagement, and digital teams that want objective performance benchmarks and a clear read on where strategy, investment, and optimization effort should go next. Understand where you stand, and where the competitive advantage is available.
Proven on live programs
before they were products.
Both products run on the frameworks behind PharmaForward’s consulting practice: the Proxy ROAS Framework, which connects digital spend to business outcomes without touching HIPAA-restricted data, and the AI Visibility Index, which scores brand presence across AI answer engines like a media channel.
Digital Intelligence was built and proven inside a live rare disease gene therapy program before it was offered to anyone else. The interpretation layer exists because we do this work daily, on real brands, inside real MLR and compliance constraints.
See an edition
before you decide.
These products come out of the PharmaForward consulting practice — the same team, applied at scale. See how PharmaForward works with biopharma teams → PharmaForward works with a small number of brands at a time. If your reporting stops at what happened, that’s the conversation to have.